You are here: Home: Audio Program Guide: LCU 4 | 2006 Audio: LCU 4 | 2006

  Go to interview with Alan B Sandler, MD
Go to interview with Vincent A Miller, MD
Go to interview with Harvey I Pass, MD
Go to interview with Thomas E Stinchcombe, MD
   
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
 
Sandler Alan B Sandler, MD
Associate Professor of Medicine
Medical Director, Thoracic Oncology
Director, Vanderbilt-Ingram Cancer Center Affiliate Network Program
Vanderbilt University Medical Center
Division of Hematology/Oncology
Nashville, Tennessee
  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Background to ECOG trial E4599: Carboplatin/paclitaxel with or without bevacizumab
Track 3 ECOG-E4599: Side effects and toxicity
Track 4 Factors associated with pulmonary hemorrhage in patients with lung cancer treated with bevacizumab
Track 5 Track 5 ECOG-E4599 subset analysis of survival by gender
Track 6 Prospective correlative assessment of biomarkers in E4599
Track 7 Updated analysis of patient deaths in E4599
Track 8 Clinical implications of E4599
Track 9 NCT00095225: Bevacizumab with chemotherapy (docetaxel or pemetrexed) or erlotinib compared to chemotherapy alone for recurrent or refractory non-small cell lung cancer (NSCLC)
Track 10 Potential role for bevacizumab/erlotinib without chemotherapy
Track 11 ECOG-E1505 adjuvant study of chemotherapy with or without bevacizumab
Track 12 Development of the EGFR and VEGF tyrosine kinase inhibitor ZD6474 (Zactima™)
Track 13 Potential advantages of nanoparticle paclitaxel in the treatment of lung cancer
 
Miller Vincent A Miller, MD
Associate Attending Physician
Thoracic Oncology Service
Memorial Sloan-Kettering Cancer Center
New York, New York
  
  Click here to download entire interview  
Track 1 Introduction
Track 2 EGFR mutation and copy number as predictors of response to erlotinib
Track 3 Availability, quality control and indications for EGFR mutation analysis
Track 4 Obtaining adequate tissue for EGFR mutation analysis
Track 5 Ethnicity as a predictor of response to tyrosine kinase inhibitors (TKIs)
Track 6 Importance of evaluating smoking status in clinical practice and trials
Track 7 Use of cigarette-smoking history to estimate the likelihood of EGFR mutations and response to TKIs
Track 8 Selection of first-line therapy for nonsmokers
Track 9 Continuation of erlotinib after disease progression
Track 10 Ongoing clinical trials evaluating erlotinib
Track 11 Topical vitamin K to prevent erlotinib- and cetuximab-associated rash
Track 12 ECOG-E1505 adjuvant study of chemotherapy with or without bevacizumab
Track 13 Bevacizumab-associated side effects and toxicity and implications for adjuvant therapy
Track 14 Update of CALGB-9633: Adjuvant chemotherapy for Stage IB NSCLC
Track 15 Treatment algorithm for patients with Stage IA/B NSCLC
Track 16 Treatment of patients with Stage II disease
Track 17 Therapeutic approach to patients with advanced NSCLC
Track 18 Future clinical research strategies in NSCLC
Track 19 Research reports of novel agents in lung cancer reported at ASCO 2006
 
Pass Harvey I Pass, MD
Professor of Cardiothoracic Surgery and Surgery
Chief, Division of Thoracic Surgery and Thoracic Oncology
Department of Cardiothoracic Surgery
NYU School of Medicine and NCI Cancer Center
New York, New York
  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Induction chemotherapy with or without radiation therapy for Stage IIIA disease
Track 3 Clinical management of Stage IIIA disease
Track 4 Mortality of right versus left pneumonectomy
Track 5 Impact of surgical volume and outcomes
Track 6 Potential complications of preoperative radiation therapy and chemotherapy
Track 7 RTOG-0412: Neoadjuvant cisplatin/docetaxel with or without thoracic conformal radiation therapy followed by surgical resection and docetaxel for Stage IIIA NSCLC
Track 8 Surgeon’s perspective on adjuvant chemotherapy for Stage IA/B disease
Track 9 Incorporation of novel targeted agents into induction and adjuvant clinical trials
Track 10 Use of PET in clinical practice
Track 11 Evolving surgical technologies in the diagnosis and treatment of lung cancer
 
Stinchcombe Thomas E Stinchcombe, MD
Clinical Assistant Professor
Department of Hematology/Oncology
Multidisciplinary Thoracic Oncology Program
University of North Carolina
Chapel Hill, North Carolina
  
  Click here to download entire interview  
Track 1 Introduction
Track 2 Clinical trial experience with nanoparticle albumin-bound (nab) paclitaxel in lung cancer
Track 3 Potential clinical advantages of nab paclitaxel for lung cancer
Track 4 Resolution of neuropathy with nab versus standard paclitaxel formulation
Track 5 Scheduling of nab paclitaxel in the treatment of lung cancer
Track 6 Clinical development of nab paclitaxel for lung cancer
Track 7 CALGB-9633 trial of adjuvant carboplatin/paclitaxel for Stage IB disease
Track 8 Clinical trial experience with adjuvant carboplatin/docetaxel
Track 9 Incorporating bevacizumab into adjuvant clinical trials
Track 10 Clinical questions in the treatment of Stage III NSCLC
Track 11 Incorporating multikinase inhibitors into lung cancer clinical trials
Track 12 Side effects and tolerability of sunitinib in patients with lung cancer